Lauren R Violette, Jakar Delacruz, Lisa A Niemann, Chase Cannon, Joanne D Stekler, David A Katz
{"title":"在华盛顿州西雅图市，顺性男性、跨性别者和与男性发生性关系的非二元性个体对HIV PrEP产品和递送模式的偏好：一项离散选择实验。","authors":"Lauren R Violette, Jakar Delacruz, Lisa A Niemann, Chase Cannon, Joanne D Stekler, David A Katz","doi":"10.1097/QAI.0000000000003718","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Understanding preferences for HIV pre-exposure prophylaxis (PrEP) products and delivery models could better meet the needs of populations likely to benefit from PrEP and ultimately increase uptake.</p><p><strong>Setting: </strong>Public Health - Seattle & King County Sexual Health Clinic.</p><p><strong>Methods: </strong>Between August 2022-December 2023, a convenience sample of individuals seeking HIV testing and participating in Project DETECT2 completed a discrete choice experiment (DCE). We used a D-efficient blocked fractional design and asked participants to choose between two hypothetical PrEP options composed of five attributes (modality, efficacy, dosing frequency, prescriber, and monitoring appointment format). We used multinomial logistic regression to estimate preference weights and relative importance overall and stratified by PrEP experience.</p><p><strong>Results: </strong>325 participants completed the DCE; 96 (29.5%) were PrEP-naïve and 229 (70.5%) were PrEP-experienced. Ninety-nine percent efficacy (weight=0.848, 95%CI= 0.769-0.927), 6-month dosing interval (weight=0.381, 95%CI= 0.293-0.469) and pills (weight=0.173, 95%CI= 0.085-0.261) were most preferred. There was a strong preference for PrEP delivery within a pharmacy (weight=0.144, 95%CI= 0.059-0.228) or community-based organization (weight=0.097, 95%CI= 0.011-0.183). Preference for combination online/in-person (weight=0.086, 95%CI= 0.017-0.154) and in-person only monitoring appointments (weight=0.061, 95%CI= -0.023-0.144) was similar. Efficacy had the highest relative importance (52.1%). Stratifying by PrEP experience did not change preference.</p><p><strong>Conclusions: </strong>Participants preferred products with high efficacy and longer dosing intervals delivered in non-clinical spaces with in-person or online follow-up appointments. These data suggest that, while highly efficacious, longer-acting products are preferred, a range of different modalities, prescribers, and monitoring methods may be needed to reach everyone who may benefit from PrEP.</p>","PeriodicalId":520658,"journal":{"name":"Journal of acquired immune deficiency syndromes (1999)","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Preferences for HIV PrEP Products and Delivery Models Among Cisgender Men, Transgender Persons, and Non-binary Individuals Who Have Sex with Men in Seattle, Washington: A Discrete Choice Experiment.\",\"authors\":\"Lauren R Violette, Jakar Delacruz, Lisa A Niemann, Chase Cannon, Joanne D Stekler, David A Katz\",\"doi\":\"10.1097/QAI.0000000000003718\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Understanding preferences for HIV pre-exposure prophylaxis (PrEP) products and delivery models could better meet the needs of populations likely to benefit from PrEP and ultimately increase uptake.</p><p><strong>Setting: </strong>Public Health - Seattle & King County Sexual Health Clinic.</p><p><strong>Methods: </strong>Between August 2022-December 2023, a convenience sample of individuals seeking HIV testing and participating in Project DETECT2 completed a discrete choice experiment (DCE). We used a D-efficient blocked fractional design and asked participants to choose between two hypothetical PrEP options composed of five attributes (modality, efficacy, dosing frequency, prescriber, and monitoring appointment format). We used multinomial logistic regression to estimate preference weights and relative importance overall and stratified by PrEP experience.</p><p><strong>Results: </strong>325 participants completed the DCE; 96 (29.5%) were PrEP-naïve and 229 (70.5%) were PrEP-experienced. Ninety-nine percent efficacy (weight=0.848, 95%CI= 0.769-0.927), 6-month dosing interval (weight=0.381, 95%CI= 0.293-0.469) and pills (weight=0.173, 95%CI= 0.085-0.261) were most preferred. There was a strong preference for PrEP delivery within a pharmacy (weight=0.144, 95%CI= 0.059-0.228) or community-based organization (weight=0.097, 95%CI= 0.011-0.183). Preference for combination online/in-person (weight=0.086, 95%CI= 0.017-0.154) and in-person only monitoring appointments (weight=0.061, 95%CI= -0.023-0.144) was similar. Efficacy had the highest relative importance (52.1%). Stratifying by PrEP experience did not change preference.</p><p><strong>Conclusions: </strong>Participants preferred products with high efficacy and longer dosing intervals delivered in non-clinical spaces with in-person or online follow-up appointments. These data suggest that, while highly efficacious, longer-acting products are preferred, a range of different modalities, prescribers, and monitoring methods may be needed to reach everyone who may benefit from PrEP.</p>\",\"PeriodicalId\":520658,\"journal\":{\"name\":\"Journal of acquired immune deficiency syndromes (1999)\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of acquired immune deficiency syndromes (1999)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/QAI.0000000000003718\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of acquired immune deficiency syndromes (1999)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/QAI.0000000000003718","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Preferences for HIV PrEP Products and Delivery Models Among Cisgender Men, Transgender Persons, and Non-binary Individuals Who Have Sex with Men in Seattle, Washington: A Discrete Choice Experiment.
Background: Understanding preferences for HIV pre-exposure prophylaxis (PrEP) products and delivery models could better meet the needs of populations likely to benefit from PrEP and ultimately increase uptake.
Setting: Public Health - Seattle & King County Sexual Health Clinic.
Methods: Between August 2022-December 2023, a convenience sample of individuals seeking HIV testing and participating in Project DETECT2 completed a discrete choice experiment (DCE). We used a D-efficient blocked fractional design and asked participants to choose between two hypothetical PrEP options composed of five attributes (modality, efficacy, dosing frequency, prescriber, and monitoring appointment format). We used multinomial logistic regression to estimate preference weights and relative importance overall and stratified by PrEP experience.
Results: 325 participants completed the DCE; 96 (29.5%) were PrEP-naïve and 229 (70.5%) were PrEP-experienced. Ninety-nine percent efficacy (weight=0.848, 95%CI= 0.769-0.927), 6-month dosing interval (weight=0.381, 95%CI= 0.293-0.469) and pills (weight=0.173, 95%CI= 0.085-0.261) were most preferred. There was a strong preference for PrEP delivery within a pharmacy (weight=0.144, 95%CI= 0.059-0.228) or community-based organization (weight=0.097, 95%CI= 0.011-0.183). Preference for combination online/in-person (weight=0.086, 95%CI= 0.017-0.154) and in-person only monitoring appointments (weight=0.061, 95%CI= -0.023-0.144) was similar. Efficacy had the highest relative importance (52.1%). Stratifying by PrEP experience did not change preference.
Conclusions: Participants preferred products with high efficacy and longer dosing intervals delivered in non-clinical spaces with in-person or online follow-up appointments. These data suggest that, while highly efficacious, longer-acting products are preferred, a range of different modalities, prescribers, and monitoring methods may be needed to reach everyone who may benefit from PrEP.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
